Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum

European Journal of Pharmacology

Volumn 412, Issue 2, 2001, Pages 127-138

  Westerink, Ben H C ^a   Kawahara, Yuki ^a   De Boer, Peter ^a   Geels, Corinne ^a   De Vries, Jan B ^a   Wikström, Hakan V ^a   Van Kalkeren, Annet ^a   Van Vliet, Bernard ^b   Kruse, Chris G ^b   Long, Steve K ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Antipsychotic drug; Prefrontal cortex; Striatum

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BENZAMIDE DERIVATIVE; CLOZAPINE; DESIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; NOMIFENSINE; NORADRENALIN; OLANZAPINE; RACLOPRIDE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SEROTONIN RECEPTOR; SULPIRIDE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; MALE; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; NOREPINEPHRINE; PREFRONTAL CORTEX; RACLOPRIDE; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SULPIRIDE;

EID: 0035951616     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00935-3     Document Type: Article

References (37)

1. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system
2. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
3. Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity
4. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain
5. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
6. The effect of acetylcholinesterase inhibition on the release of acetylcholine from the striatum in vivo: Interaction with autoreceptor responses
7. Haloperidol increases and apomorphine decreases striatal dopamine metabolism after destruction of striatal dopamine-sensitive adenylate-cyclase by kainic acid
8. Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade
9. Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely moving rats
10. Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain
11. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade
12. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
13. Overcoming the neuroleptic-induced deficit syndrome: Clinical observations with remoxipride
14. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity
15. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
16. Differential action of typical and atypical antipsychotic drugs on dopamine release in the core and the shell of the nucleus accumbens
17. Clozapine potently stimulates mesocortical dopamine neurons
18. Role of serotonin in the action of atypical antipsychotic drugs
19. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
20. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex
21. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux
22. 3 dopamine receptor antagonist activity and limbic selectivity
23. Amisulpride vs. rispiridone in the treatment of acute exacerbations of schizophrenia
24. Psychommotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with atypical (amisulpride) and a classic (haloperidol) antipsychotic
25. 1A receptor activation
26. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
27. Neurochemical profile of the selective and silent 5-HT1A receptor antagonists WAY100135: An in vivo microdialysis study
28. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat
29. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
30. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors
31. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder
32. BMG80, a novel potential antipsychotic drug: Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex
33. Cortical maldevelopment, antipsychotic drugs, and schizophrenia: A search for common ground
34. On the mechanism of neuroleptic induced increase in striatal dopamine release: Brain dialysis provides direct evidence for mediation by autoreceptors localized on nerve terminals
35. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain